Yenong Cao MD, PhD
Assistant Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7523ycao25@bu.edu
Sections
Hematology & Medical Oncology
Biography
Yenong Cao, MD, PhD, is a medical oncologist specializing in gastrointestinal cancers at Boston Medical Center, and an assistant professor at Boston University Chobanian & Avedisian School of Medicine. Dr. Cao received her doctorate degree in molecular and cellular pharmacology, and medical degree from University of Miami Miller School of Medicine in Miami, Florida. She completed Internal Medicine residency at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, followed by Hematology and Oncology fellowship at Tufts Medical Center in Boston, Massachusetts.
Dr. Cao’s research interests include cancer care delivery equity and patient experience optimization, with a special focus in health technology.
Dr. Cao has authored various publications. She's also the recipient of the Journal of Clinical Oncology (JCO) Oncology Practice Editorial Fellowship and serves as a mentor for the JCO Trainee reviewer mentoring program. She's passionate about advising oncology trainees from diverse backgrounds, and support trainee wellbeing especially new trainee parents.
Publications
Cao Y, Baiyee MNB, Ching J, Murphy-Banks R, Wang FQ, Maloney A, Rodday AM, Parsons SK. Epic Patient Portal Adoption Among Vulnerable Oncology Patients in the Era of Oral Anticancer Medications. JCO Oncol Pract. 2025 Nov 19; OP2500630. PMID: 41259725.
Published on 3/28/2025Cao Y, Baiyee MNB, Ching J, Murphy-Banks R, Wang F, Maloney A, Rodday AM, Parsons SK. HSR25-151: EPIC Patient Portal Functionality: An Equity Analysis in Vulnerable Cancer Patients. J Natl Compr Canc Netw. 2025 Mar 28; 23(3.5). PMID: 40154383.
Published on 1/14/2024Parsons SK, Rodday AM, Upshaw JN, Scharman CD, Cui Z, Cao Y, Tiger YKR, Maurer MJ, Evens AM. Harnessing multi-source data for individualized care in Hodgkin Lymphoma. Blood Rev. 2024 May; 65:101170. PMID: 38290895.
Published on 8/23/2023Cao Y, Liu MC, Hanlon EL, Chen Y, Afzal MZ, Hayes CA, Hill JM. Clinical presentation of Warburg effect in aggressive lymphoma: a case report. J Med Case Rep. 2023 Aug 23; 17(1):380. PMID: 37608348.
Published on 6/22/2023Zheng S, Cao Y, Randall J, Yu H, Thomas TO. Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer. Thorac Cancer. 2023 Aug; 14(23):2269-2274. PMID: 37345618.
Published on 8/20/2021Cao Y, Afzal MZ, Shirai K. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma. BMJ Case Rep. 2021 Aug 20; 14(8). PMID: 34417242.
Published on 8/1/2021Cao Y, Afzal MZ, Shirai K. Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. J Thorac Dis. 2021 Aug; 13(8):4668-4677. PMID: 34527308.
Published on 8/19/2016Moon Y, Cao Y, Zhu J, Xu Y, Balkan W, Buys ES, Diaz F, Kerrick WG, Hare JM, Percival JM. GSNOR Deficiency Enhances In Situ Skeletal Muscle Strength, Fatigue Resistance, and RyR1 S-Nitrosylation Without Impacting Mitochondrial Content and Activity. Antioxid Redox Signal. 2017 Feb 01; 26(4):165-181. PMID: 27412893.
Published on 10/6/2015Cao Y, Balkan W, Hare JM. S-nitrosylation and MSC-mediated body composition. Oncotarget. 2015 Oct 06; 6(30):28517-8. PMID: 26415218.
Published on 7/15/2015Hatzistergos KE, Paulino EC, Dulce RA, Takeuchi LM, Bellio MA, Kulandavelu S, Cao Y, Balkan W, Kanashiro-Takeuchi RM, Hare JM. S-Nitrosoglutathione Reductase Deficiency Enhances the Proliferative Expansion of Adult Heart Progenitors and Myocytes Post Myocardial Infarction. J Am Heart Assoc. 2015 Jul 15; 4(7). PMID: 26178404.